Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions

Journal of Clinical Oncology

Volumn 18, Issue 11, 2000, Pages 2316-2326

  Trask, Peter C ^a   Esper, Peg ^a   Riba, Michelle ^a   Redman, Bruce ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DELORAZEPAM; FLUOXETINE; INTERFERON; LYMPHOBLAST INTERFERON; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DEPRESSION; HUMAN; MENTAL DISEASE; MENTAL HEALTH CARE; PATIENT REFERRAL; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RATING SCALE; REVIEW; SUICIDE;

EID: 0034118647     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.11.2316     Document Type: Review

References (79)

1. Borden E, Parkinson D: A perspective on the clinical effectiveness and tolerance of interferon-α. Semin Oncol 25:3-8, 1998 (suppl 1)
2. Baron S, Tyring SK, Fleischmann WR, et al: The interferons: Mechanisms of action and clinical applications. JAMA 266:1375-1383, 1991
3. Kirkwood JM, Ernstoff MS: Interferons: Clinical applications -Cutaneous melanoma, in DeVita VT Jr, Hellman, S. Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, JB Lippincott, 1991, pp 311-333
4. Pestka S, Langer J, Zoon K, et al: Interferons and their actions. Ann Rev Biochem 56:727-777, 1987
5. Samuel CE: Mechanisms of the antiviral action of interferons. Prog Nucl Acid Res Mol Biol 35:27-72, 1988
6. Goodkin DE: Interferon beta treatment for multiple sclerosis: Persisting questions. Mult Scler 2:321-324, 1996
7. Quesada JR, Talpaz M, Rios: A, et al: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 4:234-243, 1986
8. Yokoyama A, Kimura Y, Shigemura J: Psychiatric side effects of interferon. J Toxicol Sci 21:93-96, 1996
9. Valentine AD, Meyers CA, Kling MA, et al: Mood and cognitive side effects of interferon-α therapy. Semin Oncol 25:39-47, 1998 (suppl 1)
10. Weiss K: Safety profile of interferon-α therapy. Semin Oncol 25:9-13, 1998 (suppl 1)
11. Bocci V: Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeos Agents 2:107-118, 1988
12. Meyers CA, Scheibel RS, Forman AD: Persistent neurotoxicity of systemically administered interferon-α. Neurology 41:672-676, 1991
13. Miller RL, Steis RG, Clark JW, et al: Randomized trial of α2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 49:1871-1876, 1989
14. McDonald EM, Mann AH, Thomas HC: Interferons as mediators of psychiatric morbidity. Lancet 2:1175-1178, 1987
15. Merimsky O, Chaitchik S: Neurotoxicity of interferon-α. Anti-cancer Drugs 3:567-570, 1992
16. Spiegel RJ: The alpha interferons: Clinical overview. Semin Oncol 14:1-12, 1987 (suppl 2)
17. Valentine AD, Meyers CA, Talpaz M: Treatment of neurotoxic side effects of interferon-α with naltrexone. Cancer Invest 13:561-566, 1995
18. Janssen HLA, Brouwer JT, van der Mast RC, et al: Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 21:241-243, 1994
19. Renault PF, et al: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147:1577-1580, 1987
20. Van Thiel DH, Friedlander L, Maria ND, et al: Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepatogastroenterol 45:328-330, 1998
21. Levenson JL, Fallon HJ: Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 88:760-761, 1993
22. Goldman LS: Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 35:412-413, 1994
23. Van Thiel DH, Friedlander L, Molloy PJ, et al: Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 7:165-168, 1995
24. Fukunishi K, Tanaka H, Maruyama J, et al: Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 24:581-583, 1998
25. Malaguarnera M, Fazio ID, Restuccia S, et al: Interferon alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha. Neuropsychobiology 37: 93-97, 1998
26. Donnelly S: Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum 25:921-927, 1998
27. Mohr DC, Goodkin DE, Likosky W, et al: Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 54:531-533, 1997
28. Pavol MA, Meyers CA, Rexer JL, et al: Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 45:947-950, 1995
29. Iancu I, Sverdlik A, Dannon PN, et al: Bipolar disorder associated with interferon-alpha treatment. Postgrad Med J 73:834-835, 1997
30. Strite D, Valentine AD, Meyers CA: Manic episodes in two patients treated with interferon alpha. J Neuropsychiatry 9:273-276, 1997
31. Valentine AD, Meyers CA: Successful treatment of interferon-α-induced mood disorder with nortriptyline. Psychosomatics 35:418-419, 1995
32. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
33. Mapou RL, Law WA, Wagner K, et al: Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 8:74-81, 1996
34. Adams F, Quesada J, Gutterman JU: Neuropsychiatrie manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 252:938-941, 1984
35. Niiranen A, Laaksonen R, Iivanainen M, et al: Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr Scand 78:622-626, 1988
36. Wyatt RJ, Portnow B, Kupfer DJ: Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 24:65-70, 1971
37. Roy A, Pickar D, Linnoila M, et al: Plasma norepinephrine levels in affective disorders. Arch Gen Psychiatry 42:1181-1185, 1985
38. Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology (ed 5). New York, NY, Oxford University Press, 1986
39. Ashton H: Brain Function and Psychotropic Drugs. New York, NY, Oxford University Press, 1992
40. Benton D: The role of opiate mechanisms in social relationships, in Lader M (ed): The Pharmacology of Addiction. New York, NY, Oxford University Press, 1988, pp 115-140
41. Lindstrom LH, Widerlov E, Gunne L: Endorphins in human cerebrospinal fluid: Clinical correlates to some psychotic states. Acta Psychiatr Scand 57:153-164, 1978
42. Newnham JP, Tomlin S, Ratter SJ, et al: Endogenous opioids in pregnancy. Br J Obstet Gynaecol 90:535-538, 1983
43. Pickar D, Culler NR, Naber D, et al: Plasma opioid activity in manic-depressive illness. Lancet 1:937, 1980
44. Terenius L: Physiological and clinical relevance of endorphins. Communication to symposium on Centrally Acting Peptides. Biological Council, Middlesex Hospital Medical School, London, United Kingdom, April 4-5, 1977
45. von Knorring L, Almay BG, Johansson F, et al: Pain perception and endorphin levels in cerebrospinal fluid. Pain 5:359-365, 1978
46. Blalock JE, Smith EM: Human leukocyte interferon (HuIFN-α): Potent endorphin-like opioid activity. Biochem Biophys Res Commun 101:472-478, 1981
47. Dafny N, Prieto-Gomez B, Reyes-Vasquez C: Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity. J Neuroimmunol 9:1-12, 1985
48. Ho BT, Huang JT: Role of dopamine in d-amphetamine-induced discriminative responding. Pharmacol Biochem Behav 2:1085-1092, 1975
49. Ho BT, Huo Y, Lu J, et al: Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-α. Pharmacol Biochem Behav 42:57-60, 1992
50. Rothschild AJ, Schatzberg AF, Langlais PJ, et al: Psychotic and non-psychotic depression: I. Comparison of plasma catecholamines and cortisol measures. Psychiatry Res 20:143-153, 1987
51. Mazure CM, Bowers MB, Hoffman F, et al: Plasma catecholamine metabolites in subtypes of major depression. Biol Psychiatry 22:1469-1472, 1987
52. Hamner MB, Diammond BI: Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: A pilot study. Psychiatry Res 64:209-211, 1996
53. Meyers CA, Obbens EA, Scheibel RS, et al: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68:88-92, 1991
54. Agren H: Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: General patterns. Psychiatry Res 3:211-224, 1980
55. Asberg M, Thoren P, Traskman L, et al: "Serotonin depression:" A biochemical subgroup within the affective disorders? Science 191: 478-480, 1976
56. Asberg M, Bertilsson L, Martenssen B, et al: CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 69:201-219, 1984
57. Moller SE, Kirk L, Bandrup E, et al: Plasma tryptophan in depression. Biol Psychiatry 10:30-46, 1983
58. Brown RR, Ozaki Y, Datta SP, et al: Implications of interferon-induced tryptophan catabolism in cancer, autoimmune diseases, and AIDS. Adv Exp Med Biol 294:425-435, 1991
59. Carpiniello B, Orru M, Baita A, et al: Mania induced by withdrawal of treatment with interteron alfa. Arch Gen Psychiatry 55:88-89, 1998
60. Schildkraut JJ: Current status of the catecholamine hypothesis of affective disorders, in Lipton MA, DiMascio A, Killam KF (eds): A Generation of Progress. New York, NY, Raven Press, 1978, pp 1223-12234
61. Bourne HR, Bunney WE, Colburn RW, et al: Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindolacetic acid in hind brains of suicidal patients. Lancet 2:805-808, 1968
62. Pare CM, Yeung DP, Price K, et al: 5-hydroxytryptophan, noradrenaline, and dopamine in brainstem, hypothalamus and caudate nucleus of controls and of patients committing suicide by gas poisoning. Lancet 2:133-135, 1969
63. Vergassola C, Pende A, Musso NR, et al: Effects of interferon α-2a on catecholamines and lymphocyte β2 adrenoceptors in healthy humans. Int J Neurosci 51:211-213, 1990
64. Vassilopoulou-Sellin R: Endocrine effects of cytokines. Oncology 8:43-46, 49-50, 1994
65. Sachithanandan S, Clarke G, Crowe J, et al: Interferon-associated thyroid dysfunction in anti-D-related chronic hepatitis C. J Interferon Cytokine Res 17:409-411, 1997
66. Fentiman IS, Balkwill FR, Thomas BS, et al: An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 24:1299-1303, 1988
67. Cavanaugh SA: Depression in medically ill: Critical issues in diagnostic assessment. Psychosomatics 36:48-59, 1994
68. Derogatis LR: SCL-90-R: Administration, scoring, and procedures manual (ed 2). Towson, MD, Clinical Psychometric Research, 1983
69. Wolkowitz OM, Reus VI: Treatment of depression with anti-glucocorticoid drugs. Psychosomatic Medicine 61:698-711, 1999
70. Maes S, Song C, Lin AH, et al: Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and stimulation or interleukin-10 secretion. Neuropsychopharmacol 20:370-379, 1999
71. Maes M, Scharpe S, Meltzer HY, et al: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res 54:143-160, 1994
72. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (ed 4). Washington, DC, American Psychiatric Association, 1994
73. Derogatis LR, Melisaratos N: The Brief Symptom Inventory: An introductory report. Psychol Med 13:595-605, 1983
74. Derogatis LR: The Brief Symptom Inventory (BSI) Administration, Scoring and Procedures Manual II. Towson, MD, Clinical Psychometric Research, 1992
75. Beck AT, Steer RA: Beck Depression Inventory Manual. New York, NY, The Psychological Corporation, Harcourt Brace Jovanovich, 1987
76. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370, 1983
77. Spielberger CD: Manual for the State-Trait Anxiety Inventory: STAI (Form Y). Palo Alto, CA, Consulting Psychologists Press, 1983
78. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 26:112S-1121S, 1997 (suppl 1)
79. Lewinsohn PM: A behavioral approach to depression, in Friedman RJ, Katz MM (eds): The Psychology of Depression: Contemporary Theory and Research. Washington, DC, Winston, 1974